[Non-surgical treatment of benign prostatic hypertrophy. Current status of the problem].
Benign prostatic hypertrophy is a highly prevalent disease, with a significant morbidity. Classical surgical therapy (open or transurethral adenomectomy) is very effective, but not without risks and complications. Better understanding of the pathogenesis of the disease have led to the development of several alternative treatments. Hormonal treatments are briefly reviewed, especially the preliminary results obtained with the 5-alpha-reductase inhibitors.
Van Cangh
P J
PJ
Département de Chirurgie, Service d'Urologie des Cliniques universitaires St-Luc, Université catholique de Louvain-en-Woluwe.
D000726:Androgen Antagonists / Q000627:therapeutic use*; D047072:Aromatase Inhibitors; D042944:Cholestenone 5 alpha-Reductase; D017373:Cyproterone Acetate / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005485:Flutamide / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D006801:Humans; D008297:Male; D010088:Oxidoreductases / Q000037:antagonists & inhibitors; D011372:Progestins / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000601:surgery
D000726:Androgen Antagonists; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D011372:Progestins; D007987:Gonadotropin-Releasing Hormone; D017373:Cyproterone Acetate; D005485:Flutamide; D010088:Oxidoreductases; D042944:Cholestenone 5 alpha-Reductase